Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

Two years of empagliflozin slowed kidney disease progression or cardiovascular death. In this post-trial study, empagliflozin had additional cardiorenal benefits after discontinuation.

​   The New England Journal of Medicine: Search Results in Cardiology